We focus AML with mutations of the Nucleophosmin gene (NPM1) and show evidence to suggest that wild-type NPM1 has an inhibitory influence on BRD4 that is relieved upon NPM1c mutation and ...
Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...
Hosted on MSN6d
HURA: Initiating an Immune ResponseHURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...
Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...
Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...
KOMET-001 trial met its primary endpoint for ziftomenib in R/R NPM1-mutant AML, with statistically significant CR and CRh rates. Kura plans to submit an NDA for ziftomenib in Q2 2025 and initiate ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML ... On the other hand, NPM1 mutation also was noted as a favorable prognostic factor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback